Zhu Yan, Zhang Zhenzhong, Chen Shuangqing, Bai Genji, Xu Qingqing, Zhang Lili, Gao Max, Ruan Aichao, Guo Lili
Department of Radiology, the Affiliated Huai'an No.1 People's Hospital of Nanjing Medical University, Huai'an, Jiangsu, China.
Department of Thoracic Surgery, the Affiliated Huai'an No.1 People's Hospital of Nanjing Medical University, Huai'an, Jiangsu, China.
Front Oncol. 2025 Mar 13;15:1508477. doi: 10.3389/fonc.2025.1508477. eCollection 2025.
The treatment of locally advanced oesophageal squamous cell carcinoma (LAESCC) without distant metastasis remains a subject of debate. Neoadjuvant immunochemotherapy (NIC) combined with surgery is the preferred initial approach for managing LAESCC. However, information on the clinical efficacy and survival of patients with LAESCC treated with NIC followed by surgery is limited.
This retrospective analysis aimed to identify predictors NIC treatment effectiveness and on patient survival. We developed a Cox proportional hazards model and Kaplan-Meier curve to estimate progression-free survival (PFS) and overall survival (OS) following NIC treatment and surgery.
Overall, 225 patients with LAESCC were divided into training (157) and test set (68) (7:3). After a median follow-up of 2.86 years, death was observed as a positive event in 41 patients (26.1%). It is statistically significant to construct a prediction model combining radiomics features pre- and post-NIC with clinical features to predict the PFS and OS of LAESCC. The combined model showed the highest performance in predicting both disease-free survival and OS compared with the clinical or radiomics models. multivariate Cox regression analysis identified smoking (HR = 1.417, 95% confidence interval [CI]: 0.875-2.293, p = 0.156), Ki67(HR = 2.426, 95% confidence interval [CI]: 1.506-3.908, p = 0.000) and postRad-S1 (HR = 1.867, 95% CI: 1.053-3.311, p = 0.033) as significant independent covariates associated with high PFS. While Ki67 and postRad-S2 were prognostic factors significantly associated with OS (HR = 1.521, 95% CI: 0.821-2.818, p = 0.183; HR = 1.912, 95% CI: 1.001-3.654, p = 0.050, respectively).
For patients with LAESCC treated with NIC followed by surgery, the combined model effectively evaluated the efficacy of NIC and predicted PFS and OS. Additionally, different independent predictors were associated with PFS and OS, providing clues for future studies.
局部晚期食管鳞状细胞癌(LAESCC)且无远处转移的治疗仍是一个有争议的话题。新辅助免疫化疗(NIC)联合手术是治疗LAESCC的首选初始方法。然而,关于接受NIC后手术治疗的LAESCC患者的临床疗效和生存情况的信息有限。
本回顾性分析旨在确定NIC治疗效果和患者生存的预测因素。我们建立了Cox比例风险模型和Kaplan-Meier曲线,以估计NIC治疗和手术后的无进展生存期(PFS)和总生存期(OS)。
总体而言,225例LAESCC患者被分为训练集(157例)和测试集(68例)(7:3)。中位随访2.86年后,41例患者(26.1%)出现死亡这一阳性事件。构建一个将NIC前后的影像组学特征与临床特征相结合的预测模型来预测LAESCC的PFS和OS具有统计学意义。与临床或影像组学模型相比,联合模型在预测无病生存期和OS方面表现出最高的性能。多因素Cox回归分析确定吸烟(HR = 1.417,95%置信区间[CI]:0.875 - 2.293,p = 0.156)、Ki67(HR = 2.426,95%置信区间[CI]:1.506 - 3.908,p = 0.000)和Rad-S1后(HR = 1.867,95% CI:1.053 - 3.311,p = 0.033)是与高PFS相关的显著独立协变量。而Ki67和Rad-S2后是与OS显著相关的预后因素(HR分别为1.521,95% CI:0.821 - 2.818,p = 0.183;HR = 1.912,95% CI:1.001 - 3.654,p = 0.050)。
对于接受NIC后手术治疗的LAESCC患者,联合模型有效地评估了NIC的疗效并预测了PFS和OS。此外,不同的独立预测因素与PFS和OS相关,为未来研究提供了线索。